# NAD+ Peptide

> NAD+ is the cellular redox coenzyme itself, with compounded injectable, nasal, and topical presentations kept separate from NMN and NR precursors.

Canonical: https://pepflow.app/peptides/nad-plus/

The Cellular Cofactor

NAD+ is the oxidized nicotinamide adenine dinucleotide coenzyme itself—not the precursors NMN or NR—with compounded injectable, nasal, and topical presentations.

NAD+ aging biology  Metabolic health

Tier D

Evidence Preliminary

Safety Limited Data

FDA status Not Approved

Topical 503A Not Listed

Last reviewed October 25, 2026 20 citations [How to read these labels](<https://pepflow.app/peptide-label-legend/>)

## What is NAD+?

NAD+ is a cellular redox coenzyme involved in energy metabolism and enzyme signaling. Direct NAD+ products are chemically distinct from NMN and nicotinamide riboside.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/31572171/>) [\[14\]](<https://clinicaltrials.gov/study/NCT06919328>) [\[15\]](<https://pubmed.ncbi.nlm.nih.gov/42380286/>)

Direct NAD+ injectable, nasal, and topical preparations are compounded products rather than FDA-approved drug presentations. Their exact concentration and pharmacy instructions control the calculation.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/31572171/>) [\[14\]](<https://clinicaltrials.gov/study/NCT06919328>) [\[15\]](<https://pubmed.ncbi.nlm.nih.gov/42380286/>) For more context, read the [NAD+ injection and precursor explainer](<https://pepflow.app/blog/nad-injections/>).

## What NAD+ is investigated for

NAD+ evidence is grouped by practical use case and injectable, nasal, topical, and intravenous route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

### ### Cardiac function Injectable 56% Emerging

This is a limited human signal for one IV clinical context, not evidence for subcutaneous, nasal, topical, or general anti-aging use.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40954388/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41655607/>)

#### Human evidence

A randomized placebo-controlled trial in 180 adults with heart failure from ischemic cardiomyopathy reported improved left-ventricular ejection fraction at one month after a short intravenous course. It was single-center, used IV delivery, and did not establish broader clinical-event or wellness benefits.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40954388/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41655607/>)

#### Animal / mechanistic evidence

Mechanistic and preclinical NAD+ literature supports cardiovascular plausibility but cannot replicate the human clinical result.[\[10\]](<https://pubmed.ncbi.nlm.nih.gov/17161604/>) [\[13\]](<https://pubmed.ncbi.nlm.nih.gov/27825999/>)

### ### Olfactory recovery Nasal 28% Limited

The evidence is preclinical and cannot establish effectiveness or a human treatment timeline.[\[15\]](<https://pubmed.ncbi.nlm.nih.gov/42380286/>)

#### Human evidence

No controlled human intranasal outcome trial was identified for olfactory recovery.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41655607/>) [\[15\]](<https://pubmed.ncbi.nlm.nih.gov/42380286/>)

#### Animal / mechanistic evidence

Cultured human olfactory stem cells and a mouse anosmia model showed biological and functional signals after intranasal NAD+.[\[15\]](<https://pubmed.ncbi.nlm.nih.gov/42380286/>)

### ### Energy or fatigue support Injectable, Nasal, Topical 16% Insufficient

Energy and fatigue benefits remain unproven for the reviewed compounded routes.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/37971292/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41655607/>)

#### Human evidence

Systematic reviews found no eligible controlled direct IV or IM NAD+ outcome trials supporting common anti-aging or wellness claims through the reviewed search windows.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/37971292/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41655607/>)

#### Animal / mechanistic evidence

NAD+ is essential to energy metabolism, but biochemical necessity is not evidence that direct administration improves fatigue.[\[10\]](<https://pubmed.ncbi.nlm.nih.gov/17161604/>) [\[12\]](<https://pubmed.ncbi.nlm.nih.gov/25837229/>)

### ### Healthy aging and longevity Injectable, Nasal, Topical 14% Insufficient

Healthy-aging claims are mechanistically plausible but clinically unestablished for direct NAD+.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41655607/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/42135539/>)

#### Human evidence

No human trial has shown that direct NAD+ extends lifespan or prevents age-related disease. Human blood NAD+ findings also vary by tissue and measurement approach.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/22848760/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41655607/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/42135539/>)

#### Animal / mechanistic evidence

Reviews describe age-related NAD+ biology and extensive preclinical rationale, mostly involving pathway manipulation or precursors rather than these direct compounded routes.[\[13\]](<https://pubmed.ncbi.nlm.nih.gov/27825999/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/32097708/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/41812700/>)

## Evidence snapshot

### Overall confidence

Preliminary

40%

Direct NAD+ has documented compounded forms and limited human research, but no established route-matched wellness treatment standard.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/31572171/>) [\[14\]](<https://clinicaltrials.gov/study/NCT06919328>) [\[15\]](<https://pubmed.ncbi.nlm.nih.gov/42380286/>)

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

38%

### Human evidence

Preliminary

Small infusion and experimental injection studies provide early human context.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/31572171/>) [\[14\]](<https://clinicaltrials.gov/study/NCT06919328>)

28%

### Animal / preclinical

Limited

Intranasal NAD+ evidence includes cell and mouse-model work rather than human nasal outcomes.[\[15\]](<https://pubmed.ncbi.nlm.nih.gov/42380286/>)

55%

### Mechanism support

Emerging

NAD+ is a central cofactor, but direct administration does not automatically establish tissue delivery or durable clinical benefit.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/31572171/>) [\[14\]](<https://clinicaltrials.gov/study/NCT06919328>) [\[15\]](<https://pubmed.ncbi.nlm.nih.gov/42380286/>)

## Forms & administration

Direct NAD+ is offered in compounded powder vials, metered nasal sprays and topical creams, with separate investigational intravenous formulations. Concentration and delivery requirements are product-specific; NMN and NR amounts cannot supply a dose for direct NAD+.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/31572171/>)

Injectable Nasal spray Topical Intravenous

## Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

### Typical Range

Common protocol doses are 50 mg by injection, 30 mg intranasally, and 100 mg topically per application.

### Frequency

Injections are scheduled 3 times weekly. Intranasal and topical products are used once daily.

### Timing Considerations

Morning is the default timing for all three routes.

### Cycle Length

The injectable cycle runs 30 days. Intranasal and topical schedules are ongoing.

[Full NAD+ dosage guide](<https://pepflow.app/peptides/nad-plus/dosage/>)

## What to expect

### First hours (intravenous research only)

A small IV pilot showed rapid plasma and urine metabolite changes during a six-hour infusion; this describes handling of NAD+, not a proven symptom response.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/31572171/>)

### One month (cardiac trial only)

The ischemic-cardiomyopathy trial assessed cardiac function at one month; this timing should not be generalized to wellness or other routes.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40954388/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41655607/>)

### After stopping

Durability of any clinical effect after direct NAD+ stops has not been defined for these compounded routes.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/37971292/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41655607/>)

## Safety profile

Direct NAD+ has limited route-matched human safety data. Product quality is a material risk for sterile injectables because FDA has documented serious reactions linked to excessive endotoxin in compounded NAD+ products.[\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding>) [\[17\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026>) [\[18\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)

### Cautions

- Sterile injectable product quality[\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding>) [\[17\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026>)
- Urgent reaction symptoms[\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding>) [\[17\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026>)

### What we don't know

A reliable common-adverse-effect rate, long-term safety profile, and equivalence across formulations have not been established.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/37971292/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41655607/>) [\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding>)

## Who NAD+ is not for

Route-specific avoid and medical-review notes:

- **Pregnancy or breastfeeding without clinician review**

  Pregnancy and breastfeeding safety data are insufficient for direct injectable, nasal, or topical NAD+ use.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/37971292/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41655607/>)

## Pairing notes

### Commonly included in these stacks

[**NAD+ / MOTS-c / 5-Amino-1MQ** NAD+ / MOTS-c / 5-Amino-1MQ is a mitochondrial and metabolic stack concept built around cellular energy handling. Direct NAD+ provides the redox cofactor itself, MOTS-c targets mitochondrial stress-response signaling, and 5-Amino-1MQ targets NNMT-linked nicotinamide metabolism. NAD+ MOTS-c 5-Amino-1MQ](<https://pepflow.app/stacks/nad-mots-c-5-amino-1mq/>)

### Related peptides

[NMN](<https://pepflow.app/peptides/nmn/>) [Nicotinamide Riboside (NR)](<https://pepflow.app/peptides/nicotinamide-riboside/>)

## Regulatory status

### United States

NAD+ is not FDA-approved as a drug for the reviewed routes. Compounded, supplement, and research-market availability are separate from FDA approval.[\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding>) [\[17\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026>) [\[18\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)

| Route | FDA drug approval | 503A compounding |
| --- | --- | --- |
| Injectable | Not Approved · NAD+ is not FDA-approved as a injectable drug for the reviewed use. Compounded, supplement, or research availability is separate from FDA approval.[\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding>) [\[17\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026>) [\[18\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) | Not Listed · NAD+ does not have FDA-approved injectable dosing for the reviewed use; any compounded preparation remains product- and prescriber-specific.[\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding>) [\[17\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026>) [\[18\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) |
| Nasal | Not Approved · NAD+ is not FDA-approved as a nasal drug for the reviewed use. Compounded, supplement, or research availability is separate from FDA approval.[\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding>) [\[17\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026>) [\[18\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) | Not Listed · NAD+ does not have FDA-approved nasal dosing for the reviewed use; any compounded preparation remains product- and prescriber-specific.[\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding>) [\[17\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026>) [\[18\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) |
| Topical | Not Approved · NAD+ is not FDA-approved as a topical drug for the reviewed use. Compounded, supplement, or research availability is separate from FDA approval.[\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding>) [\[17\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026>) [\[18\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) | Not Listed · NAD+ does not have FDA-approved topical dosing for the reviewed use; any compounded preparation remains product- and prescriber-specific.[\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding>) [\[17\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026>) [\[18\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) |

### Injectable

FDA drug approval

Not Approved

NAD+ is not FDA-approved as a injectable drug for the reviewed use. Compounded, supplement, or research availability is separate from FDA approval.[\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding>) [\[17\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026>) [\[18\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)

503A compounding

Not Listed

NAD+ does not have FDA-approved injectable dosing for the reviewed use; any compounded preparation remains product- and prescriber-specific.[\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding>) [\[17\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026>) [\[18\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)

### Nasal

FDA drug approval

Not Approved

NAD+ is not FDA-approved as a nasal drug for the reviewed use. Compounded, supplement, or research availability is separate from FDA approval.[\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding>) [\[17\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026>) [\[18\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)

503A compounding

Not Listed

NAD+ does not have FDA-approved nasal dosing for the reviewed use; any compounded preparation remains product- and prescriber-specific.[\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding>) [\[17\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026>) [\[18\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)

### Topical

FDA drug approval

Not Approved

NAD+ is not FDA-approved as a topical drug for the reviewed use. Compounded, supplement, or research availability is separate from FDA approval.[\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding>) [\[17\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026>) [\[18\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)

503A compounding

Not Listed

NAD+ does not have FDA-approved topical dosing for the reviewed use; any compounded preparation remains product- and prescriber-specific.[\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding>) [\[17\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026>) [\[18\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)

### International

Product-specific status must be checked in each national medicines or supplement register.

### Sports & competition

Tested athletes should obtain sport-specific review for non-approved NAD-pathway products.[\[20\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)

## How it works

NAD+ links glycolysis, the citric-acid cycle, and oxidative phosphorylation by accepting and transferring electrons. This biochemical role is established, but it does not determine how much direct compounded NAD+ reaches each tissue.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/31572171/>) [\[14\]](<https://clinicaltrials.gov/study/NCT06919328>) [\[15\]](<https://pubmed.ncbi.nlm.nih.gov/42380286/>)

Injectable, nasal, and topical formulations create different exposure conditions. Route and formulation therefore matter when interpreting direct NAD+ research and product claims.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/31572171/>) [\[14\]](<https://clinicaltrials.gov/study/NCT06919328>) [\[15\]](<https://pubmed.ncbi.nlm.nih.gov/42380286/>)

## Research gaps & open questions

What the current literature has not yet settled about NAD+:

01

Controlled human trials need to test direct subcutaneous, nasal, and topical NAD+ separately.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/31572171/>) [\[14\]](<https://clinicaltrials.gov/study/NCT06919328>) [\[15\]](<https://pubmed.ncbi.nlm.nih.gov/42380286/>)

02

Human studies should establish how much direct NAD+ or its metabolites reach target tissues after injection, nasal use, or topical use.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/31572171/>) [\[14\]](<https://clinicaltrials.gov/study/NCT06919328>) [\[15\]](<https://pubmed.ncbi.nlm.nih.gov/42380286/>)

03

Long-term safety and product-quality surveillance remain necessary for compounded injectable products.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/31572171/>) [\[14\]](<https://clinicaltrials.gov/study/NCT06919328>) [\[15\]](<https://pubmed.ncbi.nlm.nih.gov/42380286/>)

04

Independent replication is needed for the one-month cardiac-function signal, with clinical-event outcomes and longer follow-up.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40954388/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41655607/>)

05

Human research should determine which tissue-specific NAD+ measures are clinically meaningful rather than treating whole-blood NAD+ as a universal aging biomarker.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/22848760/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/42135539/>)

## Common questions

### Is NAD+ the same as NMN or NR?

No. NAD+ is the coenzyme itself; NMN and nicotinamide riboside are different precursor molecules and have separate records.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/31572171/>) [\[14\]](<https://clinicaltrials.gov/study/NCT06919328>) [\[15\]](<https://pubmed.ncbi.nlm.nih.gov/42380286/>)

### Does the selected NAD+ vial need bacteriostatic water?

Yes. The selected preset uses one 1,000 mg lyophilized NAD+ vial with exactly 5 mL bacteriostatic water, producing 200 mg/mL. A 50 mg dose is 0.25 mL or 25 U on a U-100 syringe.

### Does direct NAD+ reliably improve energy or fatigue?

That has not been established. Reviews found the direct human outcome literature too sparse to support common wellness claims, even though NAD+ is essential to cellular energy metabolism.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/37971292/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41655607/>)

### Has direct NAD+ been shown to slow aging or extend lifespan?

No human lifespan or disease-prevention benefit has been demonstrated. Aging-pathway research provides rationale, not proof of a clinical anti-aging effect.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/32097708/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41655607/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/42135539/>)

### Can IV, subcutaneous, nasal, and topical NAD+ evidence be combined?

No. Each route creates different exposure and product-quality considerations, so findings should remain route-specific.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/31572171/>) [\[14\]](<https://clinicaltrials.gov/study/NCT06919328>) [\[15\]](<https://pubmed.ncbi.nlm.nih.gov/42380286/>)

## Myths & misconceptions

### Myth

All NAD+, NMN, and NR products use the same dose.

### Reality

They are different molecules and presentations; their doses, routes, and preparation instructions are not interchangeable.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/31572171/>) [\[14\]](<https://clinicaltrials.gov/study/NCT06919328>) [\[15\]](<https://pubmed.ncbi.nlm.nih.gov/42380286/>)

### Myth

A whole-blood NAD+ result is a validated biological-aging clock.

### Reality

Human findings differ by tissue and assay, and a 2026 study found whole-blood NAD+ did not vary with age or lifestyle intervention; it is not a validated standalone aging clock.[\[6\]](<https://pubmed.ncbi.nlm.nih.gov/22848760/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/42135539/>)

### Myth

Every compounded NAD+ injectable has the same safety profile.

### Reality

Sterility and endotoxin control matter. FDA has documented serious reactions tied to contaminated compounded NAD+ injectables.[\[16\]](<https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding>) [\[17\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026>)

## History & discovery

NAD+ moved from a foundational metabolic coenzyme to a proposed therapeutic target as researchers mapped its roles in redox chemistry, signaling, and age-related biology. Modern interest in direct administration should be separated from the much larger human literature on oral precursors such as NR and NMN.[\[10\]](<https://pubmed.ncbi.nlm.nih.gov/17161604/>) [\[12\]](<https://pubmed.ncbi.nlm.nih.gov/25837229/>) [\[11\]](<https://pubmed.ncbi.nlm.nih.gov/29249689/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41655607/>)

Early fermentation research identified the coenzyme activity later understood as NAD chemistry.[\[10\]](<https://pubmed.ncbi.nlm.nih.gov/17161604/>) [\[12\]](<https://pubmed.ncbi.nlm.nih.gov/25837229/>)

A small pilot characterized plasma and urine metabolites during a six-hour intravenous NAD+ infusion.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/31572171/>)

A cardiac trial and a systematic review added human context while underscoring the lack of controlled evidence for common anti-aging and wellness use.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40954388/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/41655607/>)

## Published research 20 citations

- [\[1\] **A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD** Frontiers in Aging Neuroscience, 2019-09-12. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/31572171/>)
- [\[2\] **Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial** American Journal of Cardiovascular Drugs, 2026. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/40954388/>)
- [\[3\] **Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review** American Journal of Physiology - Endocrinology and Metabolism, 2024. review.](<https://pubmed.ncbi.nlm.nih.gov/37971292/>)
- [\[4\] **NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence** Ageing Research Reviews, 2026. review.](<https://pubmed.ncbi.nlm.nih.gov/41655607/>)
- [\[5\] **Age-related NAD+ decline** Experimental Gerontology, 2020. review.](<https://pubmed.ncbi.nlm.nih.gov/32097708/>)
- [\[6\] **Age-associated changes in oxidative stress and NAD+ metabolism in human tissue** PLOS ONE, 2012. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/22848760/>)
- [\[7\] **Human whole-blood NAD+ levels do not vary with age or lifestyle interventions** Nature Metabolism, 2026. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/42135539/>)
- [\[8\] **NAD+ as a central metabolic hub regulating the hallmarks of aging: Mechanisms and therapeutic implications** Mechanisms of Ageing and Development, 2026. review.](<https://pubmed.ncbi.nlm.nih.gov/41812700/>)
- [\[9\] **The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans** Nature Metabolism, 2026. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/41540253/>)
- [\[10\] **NAD+ metabolism in health and disease** Trends in Biochemical Sciences, 2007. review.](<https://pubmed.ncbi.nlm.nih.gov/17161604/>)
- [\[11\] **NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR** Cell Metabolism, 2018. review.](<https://pubmed.ncbi.nlm.nih.gov/29249689/>)
- [\[12\] **The human NAD metabolome: Functions, metabolism and compartmentalization** Critical Reviews in Biochemistry and Molecular Biology, 2015. review.](<https://pubmed.ncbi.nlm.nih.gov/25837229/>)
- [\[13\] **NAD and the aging process: Role in life, death and everything in between** Molecular and Cellular Endocrinology, 2017. review.](<https://pubmed.ncbi.nlm.nih.gov/27825999/>)
- [\[14\] **Absorption and Tolerability of Injectable Administration of Niagen+, as Compared to NAD+** ClinicalTrials.gov. clinical trial registry.](<https://clinicaltrials.gov/study/NCT06919328>)
- [\[15\] **Therapeutic effect of intranasal nicotinamide adenine dinucleotide in the restoration of olfactory dysfunction** Experimental & Molecular Medicine, 2026-07-01. animal.](<https://pubmed.ncbi.nlm.nih.gov/42380286/>)
- [\[16\] **FDA reminds compounders to use ingredients suitable for sterile compounding** U.S. Food and Drug Administration, 2024. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding>)
- [\[17\] **GenoGenix LLC Warning Letter** U.S. Food and Drug Administration, 2026-01-20. regulatory.](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026>)
- [\[18\] **Compounding and the FDA: Questions and Answers** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)
- [\[19\] **FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>)
- [\[20\] **The 2026 List of Prohibited Substances and Methods** World Anti-Doping Agency, 2026. regulatory.](<https://ita.sport/resource/wada-2026-prohibited-list/>)

[PepFlow library coverage](<https://pepflow.app/research/peptide-library/>)

## Quick facts

**Family**

Redox/NAD metabolism compound

**Tier**

D

**Evidence**

40% Preliminary

**Safety**

Limited Data

**FDA status**

Not Approved

**Injectable 503A**

Not Listed

**Citations**

[20 citations](<https://pepflow.app/peptides/nad-plus/#published-research>)

**Updated**

October 25, 2026

### Potential benefits

- Cardiac function
- Olfactory recovery
- Energy or fatigue support
- Healthy aging and longevity

### Also known as

- Nicotinamide adenine dinucleotide
- NAD
- Direct NAD+

## Related

- [Peptide Label Key](<https://pepflow.app/peptide-label-legend/>)
- [NAD Injections Explained: Benefits, Risks and Evidence](<https://pepflow.app/blog/nad-injections/>)
- [NAD+ dosage guide](<https://pepflow.app/peptides/nad-plus/dosage/>)
- [NAD+ / MOTS-c / 5-Amino-1MQ](<https://pepflow.app/stacks/nad-mots-c-5-amino-1mq/>)
